We show that these inhibitors suppress SLC15A4-mediated endolysosomal TLR and NOD capabilities in a variety of human and mouse immune cells; we offer evidence in their capability to suppress inflammation in vivo As well as in medical settings; and we offer insights into their system of action. Our conclusions establish SLC15A4 being a druggable tar